Select to view the solutions available in your location.
Track orders, get results, manage personal information, and more.
Order tests, track orders, get results, and more.
Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Exact Sciences is working to eradicate cancer by delivering a portfolio that gives providers the information they need to better serve their patients across the cancer care continuum — starting with familial risk.
Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
Exact Sciences expects the test to be available in 2025, pending approval.
Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
The company’s commitment to community involvement keeps paying off when employees get back from giving back.
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
The Riskguard™ test is an assessment tool that can help uncover hereditary cancer risk. The actionable results can help you better understand your patients’ risk level and management options supporting personalized care.
The Riskguard test helps inform the risk stratification for patients who have a family history of cancer by identifying variants in clinically actionable cancer-associated genes, from which you can form a customized path.
The Riskguard test can assist with informing an individualized plan for your patients who have been diagnosed with cancer. Knowing about certain gene variants can help you select optimal treatment.1-6
More ways to personalize patient care
Add the Riskguard test with our OncoExTra™ genomic profiling test to help increase the number of patients with advanced or metastatic cancer that are eligible for targeted therapies.
Pair the Riskguard test with our Oncotype DX Breast Recurrence Score® test to help inform a more comprehensive treatment plan for newly diagnosed ER+/HER2- breast cancer.
We want our results to be simple yet powerful. That’s why we only report on variants in genes you can do something about based on guidelines and published literature. We provide easy-to-understand results that providers and patients can use for personalized care planning. Just the information you need, none of the stuff you don’t.
You’ll be in the know.
We’ll reach out with updates that impact your patients after the initial results. Once they test, we’ll continue to monitor genetic research for critical changes. As new relevant data becomes available about genes, cancer risk, or medical management, we’ll let you know.*
Proactive updates and outreach
Amended reports for clinically actionable changes
Published data with actionable next steps
New guidelines and screening recommendations
Cutting-edge treatment options
Complete access to our premium customer support before, during, and after testing.
Call our customer care team for general questions at 1-866-662-6897. You can request the Riskguard test kits and ask about billing, ordering, and how to access results.
Have your patients ask customer care to connect them with a genetic specialist for more detailed questions. Your patients can learn about the Riskguard test, explore the testing process, and understand possible results and outcomes.
Ask customer care to connect you with our genetic counselors for an in-depth consult. We can help you understand and interpret Riskguard test results, including medical management options for your patient.
Coverage for eligible patients including Medicare and commercial insurance
Specialized support for billing insurance and prior authorization
Flexible payment options for patients
Call customer care at 1-866-662-6897 to request our Riskguard test kits, and we’ll send them right to your office. We offer blood and saliva kits so you can select what’s best for your patients.†
Download order form below and fax to 1-715-406-4175. Be sure to also attach order form to blood or saliva specimen and mail with kit to our lab.
OR
Submit an electronic order through our online Provider Hub at esph.exactsciences.com/login.
View patient results on our online Provider Hub. For quick and easy access, log in or create an account.
Learn More
Provides individualized genomic insights to help customize treatment for patients with HR+, HER2-early-stage breast cancer.
Offers ultra-comprehensive genomic profiling to aid in therapy selection for patients with advanced disease.
Screens average-risk individuals who are 45 years and older for colon cancer (Rx Only).
How much does this test cost?
Most insurance plans cover eligible patients including Medicare and commercial insurance. Out-of-pocket (OOP) costs for the test, if any, are determined by the patient’s insurance company. They may have co-pay, co-insurance, deductible, or non-covered charges as determined by the individual’s plan. We offer flexible payment options to help with their cost.
What is the turn-around-time (TAT)?
You should receive patient results in approximately 14 to 21 days‡ of sample submission.
What if I don't have access to a genetic counselor?
We’ll get you in touch with our genetic counselors who can help you assess your patient’s risk, interpret their results, and review medical management options. Our customer care team can help patients learn about the Riskguard test, explore the testing process, and understand possible results and outcomes or connect them to an independent genetic counselor.
Are your lab and test New York state certified?
Yes. New York State Approval Project ID 93819. For more information visit https://www.wadsworth.org/regulatory/clep/approved-ldt.
With questions about ordering the Riskguard test, insurance billing and payment options, checking results, or getting connected with a genetic counselor, call us at 1-866-662-6897 or email us at riskguard@exactsciences.com.
*The terms of this product offering are subject to change and not offered permanently or in perpetuity. Any modifications are to be considered effective once published on this website
†Risguard test kits are provided at no charge and are to be used only with the Riskguard test.
‡Data on file
References
1Geyer CE Jr, Garber JE, Gelber RD, et al; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250-1268.
2Hussain M, Mateo J, Fizazi K, et al; PROfound Trial Investigators. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345-2357.
3Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.
4Ledermann J, Harter P, Gourley C, et al : Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.
5Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
6Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69-79.
The Exact Sciences Riskguard test was developed, and its performance characteristics validated by an Exact Sciences laboratory following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The test is performed in Marshfield, WI at PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences. PreventionGenetics is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. It has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority.